Drugs and non-alcoholic steatohepatitis

Indian Journal of Pharmacology

Volumn 38, Issue 4, 2006, Pages 238-242

  Das, S ^a   Vasudevan, D ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antihypertensive drugs; Antiobesity drugs; Liver disease

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMFEPRAMONE; AMIODARONE; AMPHETAMINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; BENZPHETAMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DEXAMPHETAMINE; DEXFENFLURAMINE; ESTROGEN; FENFLURAMINE; FLUOXETINE; HEXESTROL BIS(2 DIETHYLAMINOETHYL) ETHER; LABETALOL; MAZINDOL; METHOTREXATE; METHYLDOPA; ORAL ANTIDIABETIC AGENT; PERHEXILINE MALEATE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENYLPROPANOLAMINE; REACTIVE OXYGEN METABOLITE; SIBUTRAMINE; TAMOXIFEN; TETRAHYDROLIPSTATIN; UNINDEXED DRUG;

ANGINA PECTORIS; ASTHENIA; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHOLESTASIS; CHOLESTATIC HEPATITIS; COMORBIDITY; CORNEA DISEASE; DIABETES MELLITUS; GRANULOMATOSIS; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; INSOMNIA; LIPIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER GRANULOMA; LIVER HYPERPLASIA; LIVER TOXICITY; LIVER TUMOR; LUNG INFILTRATE; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PELIOSIS HEPATIS; PERIPHERAL NEUROPATHY; REVIEW; REYE SYNDROME; STROKE; TACHYCARDIA; XEROSTOMIA;

EID: 33747624174     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.27019     Document Type: Review

References (74)

1. Ludwig J, McGill DB, Lindor KD. Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997;12:398-403.
2. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterol 2000;118:1117-23.
3. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84:1513-7.
4. Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis 2001;21:3-16.
5. Farrell GC. Drugs and non-alcoholic steatohepatitis. In: Leuschner U, James O, Dancygier H, editors. Falk Symposium 121- Steatohepatitis (NASH and ASH). Dordrecht: Kluwer Academic Publishers; 2000.
6. Farrell GC. Drug induced liver disease. Edinburgh: Churchill Livingstone, 1994.
7. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatol. 2002;35:373-9.
8. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterol 2001;120:1183-92.
9. Angulo P, Lindor KD. Insulin resistance and mitochondrial abnormalities in NASH: A cool look into a burning issue. Gastroenterol 2001;120:1281-5.
10. Kuczmarski RJ. Prevalence of overweight and weight gain in the United States. Am J Clin Nutr 1992;55:495-502.
11. Ghali P, Lindor KD. Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. Semin Liv Dis 2004;24:389-97.
12. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance. J Hepatol 1998;29:495-501.
13. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000;4:73-96.
14. Pirovino M, Muller O, Zysset T, Honegger U. Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model. Hepatol 1988;8:591-8.
15. Lullmann H, Lullmann-Rauch R, Wassermann O. Drug-induced phospholipidoses II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Rev Toxicol 1975;4:185-218.
16. Droste HT, de Vries RA. Chronic hepatitis caused by lisinopril. Neth J Med 1995;46:95-8.
17. Jeserich M, Ihling C, Allgaier HP, Berg PA, Heilmann C. Acute liver failure due to enalapril. Herz 2000;25:689-93.
18. Yeung E, Wong FS, Wanless IR, Shiota K, Guindi M, Joshi S, et al. Ramipril-associated hepatotoxicity. Arch Pathol Lab Med 2003;127:1493-7.
19. Golik A, Rubio A, Weintraub M, Byrne L. Elevated serum liver enzymes in obesity: a dilemma during clinical trials. Int J Obes 1991;15:797-801.
20. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 1991;50:330-7.
21. Montero JL, Muntane J, Fraga E, Delgado M, Costan G, Serrano M, et al. Orlistat associated subacute hepatic failure. J Hepatol 2001;34:173.
22. Mehta H, Murray B, LoIudice TA. Hepatic dysfunction due to intravenous abuse of methylphenidate hydrochloride. J Clin Gastroenterol 1984;6:149-51.
23. Cai Q, Benson MA, Talbot TJ, Devadas G, Swanson HJ, Olson JL, et al. Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc 1999;74:692-4.
24. Friedenberg FK, Rothstein KD. Hepatitis secondary to fluoxetine treatment. Am J Psychiatry 1996;153:580.
25. Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985;46:59-67.
26. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatol 2003;37:917-23.
27. Schneider HL, Hornbach KD, Kniaz JL, Efrusy ME. Chlorpropamide hepatotoxicity: report of a case and review of the literature. Am J Gastroenterol 1984;79:721-4.
28. Rigberg LA, Robinson MJ, Espiritu CR. Chlorpropamide-induced granulomas. A probable hypersensitivity reaction in liver and bone marrow. J Am Med Assoc 1976;235:409-10.
29. van Basten JP, van Hoek B, Zeijen R, Stockbrugger R. Glyburide-induced cholestatic hepatitis and liver failure. Case-report and review of the literature. Neth J Med 1992;40:305-7.
30. Petrogiannopoulos C, Zacharof A. Glibenclamide and liver disease. Diabetes Care 1997;20:1215.
31. Saw D, Pitman E, Maung M, Savasatit P, Wasserman D, Yeung CK. Granulomatous hepatitis associated with glyburide. Dig Dis Sci 1996;41:322-5.
32. Ananth JV, Ban TA, Lehmann HE. Tolbutamide jundice associated with multiple drug therapy.Can Med Assoc J 1970;103:1194.
33. Nakao NL, Gelb AM, Stenger RJ, Siegel JH. A case of chronic liver disease due to tolazamide. Gastroenterol 1985;89:192-5.
34. Bridges ME, Pittman FE. Tolazamide-induced cholestasis. South Med J 1980;73:1072-4.
35. Babich MM, Pike I, Shiffman ML. Metformin-induced acute hepatitis. Am J Med 1998;104:490-2.
36. Deutsch M, Kountouras D, Dourakis SP. Metformin hepatotoxicity. Ann Intern Med 2004;140:25.
37. Nammour FE, Fayad NF, Peikin SR. Metformin-induced cholestatic hepatitis. Endocr Pract 2003;9:307-9.
38. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003;38:434-40.
39. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med 2003;114:299-306.
40. May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular- cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002;136:449-52.
41. Dhawan M, Agrawal R, Ravi J, Gulati S, Silverman J, Nathan G, et al. Rosiglitazone-induced granulomatous hepatitis. J Clin Gastroenterol 2002;34:582-4.
42. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000;132:118-21.
43. Madonia S, Pietrosi G, Pagliaro L. Acarbose-induced liver injury in an antihepatitis C virus positive patient. Dig Liver Dis 2001;33:615-6.
44. Tomita K, Azuma T, Kitamura N, Nishida J, Tamiya G, Oka A, et al. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterol 2004;126:873-85.
45. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterol 2002;122:1924-40.
46. Lahoti S, Lee WM. Hepatotoxicity of anticholesterol, cardiovascular, and endocrine drugs and hormonal agents. Gastroenterol Clin North Am 1995;24:907-22.
47. Garovic VD. Hypertension in pregnancy: Diagnosis and treatment. Mayo Clin Proc 2000;75:1071-6.
48. Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2003;7:435-51.
49. Lafuente NG Calcium channel blockers and hepatotoxicity. Am J Gastroenterol 2000;95:2145.
50. Tabak F, Mert A, Ozaras R, Biyikli M, Ozturk R, Ozbay G, et al. Losartan-induced hepatic injury. J Clin Gastroenterol 2002;34:585-6.
51. Gonzalez-Jimenez D, Varela JM, Calderon E, Galindo J, Gonzalez de la Puente MA. Candesartan and acute liver injury. Eur J Clin Pharmacol 2000;56:769-70.
52. Kiykim A, Altintas E, Sezgin O, Sezer K, Tiftik N, Akbay E, et al. Valsartan-induced hepatotoxicity in a HBs-Ag-Positive patient. Am J Gastroenterol 2003;98:507.
53. Bas V, Erkan T, Caliskan S, Sever L, Kasapcopur O, Ozbay G, et al. Toxic hepatitis due to enalapril in childhood. Pediatr Int 2003;45:755-7.
54. Thomas LA, Cardwell MS. Acute reactive hepatitis in pregnancy induced by alpha-methyldopa. Obstet Gynecol 1997;90:658-9.
55. Tameda Y, Hamada M, Takase K, Nakano T, Kosaka Y. Fulminant hepatic failure caused by ecarazine hydrochloride (a hydralazine derivative). Hepatol 1996;23:465-70.
56. Hagmeyer KO, Stein J. Hepatotoxicity associated with carvedilol. Ann Pharmacother 2001;35:1364-6.
57. Pessayre D, Bichara M, Degott C, Potet F, Benhamou JP, Feldmann G. Perhexiline maleate-induced cirrhosis. Gastroenterol 1979;76:170-7.
58. McGovern B, Garan H, Kelly E, Ruskin JN. Adverse reactions during treatment with amiodarone hydrochloride. Br Med J 1983;287:175-80.
59. Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation 1983;68:88-94.
60. Mason JW. Amiodarone. N Eng J Med 1987;316:455-66.
61. Chang CC, Petrelli M, Tomashefski JF Jr, McCullough AJ. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. Arch Pathol Lab Med 1999;123:251-6.
62. Moffat DF, Oien KA, Dickson J, Habeshaw T, McLellan DR. Hepatocellular carcinoma after long-term tamoxifen therapy. Ann Oncol 2000;11:1195-6.
63. Smith LL, Brown K, Carthew P, Lim CK, Martin EA, Styles J, et al. Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Crit Rev Toxicol 2000;30:571-94.
64. Storen EC, Hay JE, Kaur J, Zahasky K, Hartmann L. Tamoxifen-induced submassive hepatic necrosis. Cancer J 2000;6:58-60.
65. Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, et al. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 2000;7:1299-304.
66. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995;96:2461-8.
67. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984;25:1057-64.
68. Berson A, De Beco V, Letteron P, Robin MA, Moreau C, El Kahwaji J, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterol 1998;114:764-74.
69. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57-69.
70. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
71. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001;281:1135-9.
72. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001;21:43-55.
73. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 200l;35:17-23.
74. Zimmerman HJ, Ishak KG. General aspects of drug-induced liver disease. Gastroenterol Clin North Am 1995;24:739-57.